3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Urinary Bladder Neoplasms
3
Neoplasm Metastasis
2
Thymoma
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Melanoma
1
Lymphatic Metastasis
1
Head and Neck Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 10
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
Biopsy
5
X-Rays
4
Specimen Handling
4
Phantoms, Imaging
4
Nuclear Medicine Department, Hospital
4
Magnetic Resonance Spectroscopy
4
larotrectinib
2
erdafitinib
2
ensartinib
2
ulixertinib
1
tipifarnib
1
tazemetostat
1
selpercatinib
1
palbociclib
1
olaparib
1
niraparib
1
ivosidenib
1
elacestrant
1
cabozantinib
1
alectinib
1
abemaciclib
1
Vincristine
1
Vinblastine
1
Vemurafenib
1
Topotecan
1
Temozolomide
1
RAD1901
1
Methotrexate
1
LY3023414
1
Induction Chemotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Central Nervous System Neoplasms
×
avelumab
×
30 days
×
Clear all
No trials found.